SILK - Analysts Downgrade Heart Devices Focused Silk Road Medical Cite Uncertain Prospects | Benzinga
Tuesday, Silk Road Medical Inc (NASDAQ: SILK) reported interim preliminary Q3 revenue expectation of approximately $44.4 million, up 19% Y/Y, lower than the consensus of $46.29 million.
Silk Road Medical projects FY23 revenue of $170 million-$174 million, up 23%-26% Y/Y, well below the consensus of $181.66 million and prior guidance of $180 million-$184 million.
Silk Road Medical also announced that CEO Erica Rogers plans to retire from the company after completing a succession process. Ms. Rogers will remain president and CEO of the company until her successor is appointed.
Citi downgraded the stock from Buy ...